Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Three Patent Applications Related to RNAi: Jul 31, 2008

Premium
Title: Lipid Nanoparticle-Based Compositions and Methods for the Delivery of Biologically Active Molecules
 
Number: 7,404,969
 
Filed: Oct. 24, 2006
 
Lead Inventor: Tongqian Chen, Sirna Therapeutics (Merck)
 
The invention “relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid molecules,” the patent’s abstract states. “Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles, and transfection agents that effectively transfect or deliver short interfering nucleic acid. The compositions described herein are generally referred to as formulated molecular compositions or lipid nanoparticles.
 

 
Title: Methods and Compositions Involving miRNA and miRNA Inhibitor Molecules
 
Number: 20080176766
 
Filed: Aug. 10, 2007
 
Lead Inventor: David Brown, Ambion (Asuragen)
 
The invention, the patent application’s abstract states, “concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the … invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.”
 

 
Title: Allele-Specific Silencing of Disease Genes
 
Number: 20080176812
 
Filed: Jan. 31, 2006
 
Lead Inventor: Beverly Davidson, University of Iowa
 
According to the patent application’s abstract, the invention “is directed to small interfering RNA molecules targeted against an allele of interest and methods of using these siRNA molecules.”
 

 
Title: siRNA Targeting Cyclin-Dependent Kinase Inhibitor 1B
 
Number: 20080177051
 
Filed: Oct. 30, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.”

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.